SEC Form 4Coverage since Aug 13, 2025Open-market trades only
$BEIGF insider trading
Over the last 12 months, BeOne Medicines insiders reported no purchases and 51 sales totaling $362.5M across SEC Form 4 filings. 41% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $362.5M 51 events
- Events · 12m
- 51 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 41% of events, not dollars
Side
Price · $BEIGF · 3Mvia TradingView
Top insiders · 12m
Lee Chan HenrySVP, General Counsel15× · $11.1M
OYLER JOHNChief Executive Officer12× · $336.9M
Wu XiaobinPresident and COO7× · $8.8M
Wang LaiPresident, Global Head of R&D4× · $1.2M
Ball Titus B.Principal Accounting Officer3× · $120K
All insider trades
50 of 53 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 280 | $380 | $106K | -100% | plan |
| Aug 12, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 240,810 | $359.12 | $86.5M | -100% | plan · 24 tranches |
| Aug 11, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 2,666 | $360 | $960K | -100% | plan |
| Aug 3, 2026 | Rosenberg AaronChief Financial Officer · O | ▼ Sale | 1,157 | $312.72 | $362K | -100% | — |
| Jul 30, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 1,044 | $323.69 | $338K | -100% | — |
| Jul 22, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 1,669 | $325 | $542K | -100% | plan |
| Jul 21, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 109,713 | $315.28 | $34.6M | -100% | plan · 14 tranches |
| Jul 17, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 64,628 | $312 | $20.2M | -100% | plan · 9 tranches |
| Jul 16, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 283,154 | $315.56 | $89.4M | -100% | plan · 17 tranches |
| Jul 14, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 145,861 | $305.95 | $44.6M | -100% | plan · 6 tranches |
| Jul 13, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 60,218 | $303.18 | $18.3M | -100% | plan · 15 tranches |
| Jul 8, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 664 | $302.46 | $201K | -100% | plan |
| Jun 23, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,292 | $276.26 | $357K | -100% | — |
| Jun 23, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 3,410 | $273.78 | $934K | -100% | 3 tranches |
| Jun 23, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,068 | $276.74 | $296K | -100% | — |
| Jun 16, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,357 | $266.76 | $362K | -100% | — |
| Jun 16, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 3,693 | $265.55 | $981K | -100% | 3 tranches |
| Jun 16, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 590 | $265.98 | $157K | -100% | — |
| Jun 16, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,169 | $265.39 | $310K | -100% | — |
| Jun 11, 2026 | Ball Titus B.Principal Accounting Officer · O | ▼ Sale | 169 | $257.2 | $43K | -100% | 2 tranches |
| Jun 11, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 756 | $261 | $197K | -100% | — |
| Jun 11, 2026 | Rosenberg AaronChief Financial Officer · O | ▼ Sale | 631 | $257.74 | $163K | -100% | — |
| Jun 11, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 626 | $261.2 | $164K | -100% | — |
| Jun 11, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 428 | $257.64 | $110K | -100% | — |
| Jun 11, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 1,949 | $257.24 | $501K | -100% | 4 tranches |
| Jun 8, 2026 | Ball Titus B.Principal Accounting Officer · O | ▼ Sale | 136 | $271.33 | $37K | -100% | 2 tranches |
| Jun 8, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 871 | $270.42 | $236K | -100% | 2 tranches |
| Jun 8, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,367 | $269.38 | $368K | -100% | 2 tranches |
| Jun 8, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,484 | $269.37 | $400K | -100% | 2 tranches |
| Jun 8, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 4,940 | $270.56 | $1.3M | -100% | 2 tranches |
| Jun 1, 2026 | Yi QingqingD | ▼ Sale | 235 | $279.13 | $66K | -100% | — |
| May 22, 2026 | Riva AlessandroD | ▼ Sale | 212 | $309.51 | $66K | -100% | — |
| May 22, 2026 | Dugan MargaretD | ▼ Sale | 212 | $309.6 | $66K | -100% | — |
| May 22, 2026 | Sanders Corazon (Corsee) D.D | ▼ Sale | 212 | $309.59 | $66K | -100% | — |
| May 22, 2026 | BAKER BROS. ADVISORS LPD | ▼ Sale | 2,743 | $23.85 | $65K | -1.9% | indirect |
| Apr 8, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 332 | $311.59 | $103K | -100% | plan |
| Mar 11, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 341 | $300 | $102K | -100% | plan |
| Feb 4, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 1,660 | $349.52 | $580K | -100% | plan · 2 tranches |
| Jan 7, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 664 | $331.76 | $220K | -100% | plan |
| Dec 16, 2025 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 100,000 | $306.59 | $30.7M | -100% | plan · 24 tranches |
| Dec 11, 2025 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 664 | $321.64 | $214K | -100% | plan · 2 tranches |
| Nov 26, 2025 | Sanders Corazon (Corsee) D.D | ▼ Sale | 2,627 | $340.9 | $896K | -100% | 2 tranches |
| Nov 17, 2025 | Wu XiaobinPresident and COO · O | ▼ Sale | 3,991 | $380.43 | $1.5M | -100% | 3 tranches |
| Nov 13, 2025 | Wu XiaobinPresident and COO · O | ▼ Sale | 16,009 | $365.22 | $5.8M | -100% | 10 tranches |
| Nov 12, 2025 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 996 | $349.17 | $348K | -100% | plan · 2 tranches |
| Oct 8, 2025 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 10,671 | $350.4 | $3.7M | -100% | plan · 4 tranches |
| Sep 16, 2025 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 27,803 | $325.71 | $9.1M | -100% | plan · 5 tranches |
| Sep 10, 2025 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 10,006 | $325.53 | $3.3M | -100% | plan · 5 tranches |
| Sep 9, 2025 | Wang LaiGlobal Head of R&D · O | ▼ Sale | 5,000 | $350.06 | $1.8M | -100% | plan · indirect |
| Sep 5, 2025 | Sanders Corazon (Corsee) D.D | ▼ Sale | 2,665 | $337 | $898K | -100% | — |
Every $BEIGF filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? BeOne Medicines filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BEIGF feed.